FORM PTO-1449 USE OF PATENTS AND OTHER ITEMS FOR APPLICANT'S PERFORMATION DISCLOSURE STATEMENT				ATTY. DOC T NO. 30727.0013.CIP1 09/518,501 APPLICANT: METABASIS THERAPEUTICS, INC.						
JUN 1 7	w An	se several sheets	if necessary)) ## J	FILING DATE March 5, 19		i i	GROUP: 1614		
2014	6							1014		
PATE TRADE										
			U.S. P	PATENT DOCU	IMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME		LASS_	SUB		TLING DATE
Thi	1 AQ	3,018,302	01.23.62	Bielefeld, e	t al.					<u> </u>
	AB	5,157,027	10/20 92	Biller, et al.						
V	AC	5,658,889	8/19/97	Gruber, et a	al.					
• • • • • • • • • • • • • • • • • • •										
			POREIGN	N PATENT DO	CUMENTS			<u>-</u>		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COL	UNTRY		ASS	\$UB	1	SLATION
QN	AD	0 002 062 A	30.05.78	EP (Abstract		<u> </u>	A33	CLASS	YES	NO
	AE	0 072 531 A	23,62.83	EP (Abstract						
	AF	0 158 057 A	16.10.85	EP (Abstract						
	AG	0 180 276	28.12.88	EP						
	АН	0 261 283	22.09.86	EP						
	Al	0 161 955 A	21.11.85	EPO						
	A,J	0 338 372 A	25.10.89	EPO				1		
	AK	0 353 692 A	07.02.90	EPO						
4	AL	0 481 214 A	22.04.92	EPO						
N/	AM	492 738 A	30.06.70	СН						
<u> </u>	AN	16 93 219 ₄ A	17.09.70	DE (Abstract)	1					

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO-1449 ATTY. DOG NO. Serial no. 30727.0013.CIP1 09/518,501 list of patents and other items for applicant's APPLICARIT: Information disclosure statement METABASIS THERAPEUTICS, INC. FILING DATE: GROUP: Mes saveral sheets if necessary) March 5, 1999 1614 FOREIGN PATENT DOCUMENTS DIAMINETE RIOT TRANSLATION SUB INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS CLASS DE (and English language AO U.S. Patent No. 4,952,740) 35 12 781 A1 10.04.85 AP 96/01267 A 18.01.96 WO AQ 97/03679 A 06.02.97 WO 98/09668 A AR 12.03.98 WO AS 98/39342 11.09.98 WO AT 98/39343 11.09.98 WO AU 98/39344 1.09.98 WO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) "Patent Abstracts of Japan," Vol. 1998, No. 1, 30 January 1998 & JP 09 241284 A (Yamishata Koji; Nippon Soda Co. Nd), 16 September 1997 AV DeLombaert, et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endoprotidate (NEP, EC 3.4.24.11) Inhibitors, J. Med. **AW** <u> Chem.</u> 37: 498-511 (1994) Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,225-dioxaphospharinane Series. X-Ray Molecular Structure of cis-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," J. Chem. AX Res. Synop., 5: 122-123 (1989)

AZ	Farquhar, et al., "Biologically I 72(3): 324 (1983)	Reversible Phosphate-Protective Groups," <u>J. Pharm. So</u>	<u>;i.</u>
	ell desti	calos ,	
EXAMINER: Examiner	Buch Olly	DATE CONSIDERED:	
EXAMINER: Ini line through citation	tial if reference is considered, whe	nether or not citation is in conformance with MPEP 609; Draw considered. Include a copy of this form with next	

(FDUMP)" J. Med. Chem. 38:488-495:(1995)

Farquhar, et al., "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an -2-y]!-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-o-oxyuridylic acid

AY

communication to applicant

•		0.				
	FOR	M P	T O-1 449		ATTY. DOC 1 NO. 30727.0013.CIP1	serial no. 09/518.501
				nts and other items for applicant's Mation disclosure statement	APPLICANT: METABASIS THERA	
	b ".		(°}; (°) (∪	se several sheets if necessary)	FILING DATE: March 5, 1999	Group: 1614
		1 00	E)			
/	9 ,		HTG	ER DOCUMENTS (Including Author, Ti	de, Date, Pertinent	Pages, etc.)
	TI S	TRAD!	BA	Farquhar, et al., "Synthesis and Biologica oxazaphosphorinan-2-yl)-ß-D-arabinosyl] dioxazaphosphorinan-2-yl)-ß-D-arabinosyl[ß-D-Arabinofuranosyl]adenine 5'-Monop (1985)	adenine and 9-[5'-(2-0 yl]adenine: Potential No hosphate," <u>J. Med. End</u>	xo-1,3,2- extral Precursors of 9- em. 28: 1358-1361
			B8	Farquhar, et al., "Synthesis and Biologica Fluoro-2'-deoxyuridine 5'-Phosphate," J.	ll Evaluation of Neutral <u>Med. Cham. 26:</u> 1153-	Derivatives of 5- 1158 (1983)
			ВС	Freed, et al., "Evidence For Acyloxymeth Deoxyribonucleotides as Extracellular So Cultured Cells," Biochem. Pharmac. 38/3	yl Esters of Pyrimidine Prices of Active 5'-Deox 3193-3198 (1989)	5'- tyribonucleotides in
		•	8D	Hillers, et al., Analogs of pyrimidinemono (1,4-dihydroxy-2-pentyl)thymine and 1-(1, Soedin 5:678-683 (1978). Cham Abst. v	.3-dihvdroxv-2-propvI) i	uracil." Khim Geterotski
			8E	Hunston, et al., "Synthesis and Biological Derived from 2'-Deoxy 5-fluorouridine," J.	Properties of Some Cy. Med. Chem. 27: 440-	/clic Phosphotriesters १४४ (1984)
			BF	Kryuchkov, et al. Izv. Akad. Nauk SSSR.	Ser. Khim. 6: 1201-12	48 (1987)
ĺ			BG	Lok, et al., "Neurotoxicity associated with treatment of chronic hepatitis B virus infect (1984)	adenine arabinoside m	onophosphate in the
			ВН	Ludeman, et al., "Synthesis and Antitumo Preparation, Kinetic Studies, and Anticand and Similar Compounds Related to the Cy Aldophosphamide," J. Med Chem. 29, 716	cer Screening of "Phen yclophosphamide Meta	vi ketophos phamide"
			ВІ	Meier, et al., "Cyclic Saligenyl Phosphotre didehydrothymidine (d4T) – A New Pro-No Lett. 7: 99-104 (1977)	pisters of 2', 3'-Dideoxy ucleotide Approach," <u>B</u>	-2', 3'- ioorg. Med. Chem.
			BJ	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyl Thioinosinic Acid," J. Med. Chem. 22: 811	clic 3', 5'-Phosphates (-815 (1979)	s Prodrugs of
4			BK	Neidlein, et al., "Mild Preparation of 1-Ben Application to the Synthesis of Cyclic Pho- Amides," Meterocycles 35: 1185-1203 (19	sphonic Deisters and C	honia Dichlorides: Cyclic Monoester
_				#F OKRX 11 CG		,
	EXAM: Exami	1	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	DAYE DAYE	CONSIDERED:	10
ł			- yw		7/3/	
	nué n	រលេកខែ	gh citatio	tial if reference is considered, whether or not cion if not in conformance and not considered. It	tation is in conformance nclude a copy of this form	with MPEP 609; Draw n with next
L	comit	ומוניו	ation to	applicant		

					<u></u>		
· F	DRM P		•	ATTY. DOCUMENO. 30727.0013.CIP1	SERIAL NO. 09/518,501		
	PF		ENTS AND OTHER ITEMS FOR APPLICANT'S PRINCE STATEMENT	APPLICANT: METABASIS THERAPEUTICS, INC.			
10	, . –		Use several sheets if necessary)	FILING DATE: March 5, 1999	GROUP: 1614		
	IN 1 1	<u> </u>					
\D .	TELTRAI		HER DOCUMENTS (Including Author, Ti	tle, Date, Pertinent	Pages, etc.)		
0	n	BL	Nifant'ev, et al., "1,3,2, - Diazaphodsphor 1979, Pages 64-74 (and English version a language publication)	inanes", <u>Zh. Obshch. k</u> as translated in corresp	(him., Vol. 49, No. 1, conding English		
	Nifantyev, et al., "Synthesis and Structure of Some Stable Phospholane- BM Phospholanes," Phos. Sulfur & Silicon 113, 1-13 (1996)						
		Predvoditelev D., et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Organic</u> BN Chemistry of the USSR (English Translation 13:1489-1492 (1977))					
•		во	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholipe" <u>Journal of Organic Chemistry of the USSR (English Translation</u> 17:1156-1165 (1981)				
		BP	Shaw & Cundy, "Biological Screens of PN (1993)	NEA Prodrugs," Pharm.	Res. 10 (Suppl) S24		
	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," Bull. Inst. Chem. Acad. Str., 41: 9-16 (1994)						
	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," J. Med. Chem. 37: 1957-1864 (1994)						
		BS	Yamanaka, et al., "Metabolic Studies on B Active against Hepatitis B Virus," Antimicro	MS-200475, a New Arob. Agents Chemoth.	ntiviral Comound 13, 190-193 (1999)		
	X	ВТ	Zon, ét al., "4 Cyclophosphamide Analogy				
		£	HI doflect	e c			

EXAMINER: Exampler	Dun alle	DATE CONSIDERED: 2/9/07
EXAMINER: I line through cita communication	ation if not in conformance and hot consider	not citation is in conformance with MPEP 609; Draw red. Include a copy of this form with next

	type a plus sign (*) inside this box ->
'	Substitute for form 1449A/PTO

Approved for Jugh 10/31/2002. OMB 0851-0031
S. Part and Trademark Office: DEPARTMENT OF COMMERCE
and to a collection of information unloss contains a veild OMB control number

PTO/SB/08A (08-00)

Complete If Known

NATE &
information disclosure
Statement by applicant

Application Number 09/318,501 March 3, 2000 Filing Date Erlon First Named Inventor 1624 Group Art Unit

(use es many sheets as necessary)

Sheet

T. McKenzle Examiner Name 030727.0013.CIP1 Attorney Docket Number

				U.S. PATENT DOCU	MENTS	
Examinar Initialo*	Cite No.5	U.S. Pater Number	nt Document tand Cada ³ (# tana::n)	Nome of Patentee or Applicant of Cited Document	Dato of Publication of Cited Document MM-DD-YYYY	Pagasa, Cahumma, Umasa, Whata Robovani Pagasagas at Robovani Figuras Appazor

			Foreign Patent Doc	matem	Name of Potenties or	Date of Publication of	Pages, Columns, Lines, Where Andrews	
Enominer Initials	Cite No.'	Office	Number*	(Clind Code* (g*	Applicant of Cited Document	Clied Document MM-DD-YYYY	Presences or Referent Figures Appear	1
								1
						 		╬
		 				 		╁
								┽

		non patent literature documents		
Examinar Initiala	Cite tribudo remo of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magaz No. serial, symposium, cetalog, etc.), data, page(s), volume-lesus numbor(s), putdisher, city end/or country where publisher.			
PA A		Coppi, et al., "Lewis Acid Mediated Condensation of Alkenois and Aldehydes. A Selective Synthesis of Tetrahydropyrans and Oxepanes," J. Org. Chem., Vol. 53, No. 4, 911-913 (1988)		
74.4	AB	Lohr et al., "Targeted chemotherapy by intratumor injection of encapsulated cells engineered to produce CYP2B1, and ifosfamide activating cytochrome P450," Gene Therapy, 5, 1070-1078 (1988).		
	AC	Bijsterbosch, et al., "Disposition of the Acyclic Nucleoside Phsophonate (S)-9-(3- Hydroxy-2-Phosphonylmethoxypropyl)Adenine," Antimicrobial Agents and Chemotherapy, "Vol. 42, p. 1146-1150 (May 1998).		
V	AD	de Waziers, et al., "Cytochrome P 450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues1," The Journal of Pharmacology and Experimental Therapeutics, Vol. 253, No.1, p. 387-394 (1989).		

					 =
Examiner Dis McLls	Date Considered	2/	12	03_	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be cent to the Chief Information Officer, U.S. Patent and Trademark Officer, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patenta, Washington, OC 20231.

^{*}EXAMINER: Initial if reference considered, whisther or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this temp with next communication to applicant.

¹ Unique citation designation number. ² See ettached Kinds of U.S. Petent Documents. ³ Enter Office that Issued the document, by the two-latter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emparer must precede the certai number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation in attached.

Please type a plus sign (+) inside this box 💆

FEB 2 5 2002 8

PTO/SB/08A (08-00)
Approved for Let divough 10/31/2002, OMB 0851-0031
Patent and Tradamark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no particle are required
Substitute for form 1449APTO

are required to region to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

	emplete if Known	7
Application Number	09/518,501	-
Filing Date	March 5, 1999	A le.
First Named Inventor	Erion	160 40
Group Art Unit	1624	CHO
Examiner Name	T. McKenzie	CEAN
Attorney Docket Number	030727.0013.CIP1	1/ED

		NON PATENT LITERATURE DOCUMENTS	70
Examiner Initiats	Cite No.'	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	72
TU	AE	He, et al., "Inactivation of Cytochrome P450 3A4 by Bergamottin a Component of Grapefruit Julce," Chem. Res. Toxicol, Vol. 11, No. 4, p. 252-259 (1998).	
8	AF	Jounaidi et al., "Retroviral Transfer of Human Cytochrome P450 Genes for Oxazaphosphorine-based Cancer Gene Therapy," Cancer Research, Vol. 58, p. 4391- 4401 (Oct. 1, 1998).	
	-		
	-		
•			

			1	1
maker Dund III	Date Considered	2/	13/	02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Petents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

EXAMINER INITIAL	PATER	DOCUMENT NUMBER	U.S. PA	TENT DOC	NAME	CLASS	1.7	FILING DATE
	1	FER 2 5 2007 55	•				MAR	IVEN
₩U	(Us	se several sheets if	necessary)		March 5, 19		GROUP:	
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT					METABASIS THERAPEUTICS, INC.			
FORM PTC-1449					ATTY. DOCY 30727.001		SERIAL NO 09/518,50	

Biller, et al.

Gruber, et al.

10/20/92

8/19/97

5,658,889

·	FOREIGN PATENT DOCUMENTS									
EXAMINER							SUE		TRANSLATION	
INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLA	SS_	CLAS	<u>s</u>	YES	NO
TUM	AD	0 002 062 A1	30.05.79	EP (and English language - Abstract)					,	
TU	AE	0 07 <u>2 531 A1</u>	23.02.83	EP-(and English language -Abstract)						
CM	AF	0 158 057 A	16.10.85	EP (U.K. English language translation)						•
	AG	0 180 276 A1	28.12.88	EP						
	АН	0 261 283 A1	22.09.86	EP						
	AI	0 161 955 A1	21.11.85	EPO						
	AJ	0 338 372 A2	25.10.89	EPO						
	AK	0 353 692 A2	07.02.90	EPO		~~				
	AL	0 481 214 B1	22.04.92	EPO						
	АМ	492 738	30.06.70	CH (and English language Abstract)						
$oxed{V}$	AN	987,378	17.09.70	UK					0	

EXAMINER:	Ú	DATE CONSIDERED:	18	02
EXAMINER: Initial if reference is the through citation if not in conformation to applicant	onsidered, whether or	r not citation is in conformed. Include a copy of	rma this	nce with MPEP 609; Draw form with next

FORM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several shereoff decorrany)

ATTY. DOCY NO. 30727.00 CIP1

serial no. 09/518,501

APPLICANT:

METABASIS THERAPEUTICS, INC.

Filing date: March 5, 1999 Group: 1614/2

		Page 1	LOWING!	I PATENT DOCUMENTS		MA	O SIVE
EXAMINER INITIAL		DOCUMENT NUMBER	BAAN SATE	COUNTRY	CLASS	FCEU	YES COURD
M	AO	35 12 781 A1	10.04.85	DE (and English language U.S. Patent No. 4,952,740)		777	YES <00,200
	AP	96/01267	18.01.96	wo			Ů
	AQ	97/03679	06.02.97	wo			
	AR	98/09668	12.03.98	wo			
	AS	98/39342	11.09.98	wo			
7	AT	98/39343	11.09.98	wo		<u> </u>	
	AU	98/39344	11.09.98	l wo			

	OTHER DOCUMENTS (Including Author, Title, Date, Perdinent Pages, etc.)					
N	AV	"Patent Abstracts of Japan," Vol. 1998, No. 1, 30 January 1998 & JP 09241284 A (Yamishata Koji, et al.; Nippon Soda Co. Ltd), 16 September 1997				
	AW	DeLombaert, et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopretidase (NEP, EC 3.4.24.11) Inhibitors, J. Med. Chem. 37: 498-511 (1994)				
	AX	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of cis-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," <u>J. Chem. Res. Synop.</u> , 5: 122-123 (1989)				
	AY	Farquhar, et al., "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an -2-y]!-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)" J. Med. Chem. 38:488-495 (1995)				
V	AZ	Farquhar, et al., "Biologically Reversible Phosphate-Protective Groups," <u>J. Pharm. Sci.</u> 72(3): 324-325 (1983)				

EXAMINER: Examine	Barres CMC	10	DATE CONSIDERED:	glor
	Initial if reference is considitation if not in conformance			mance with MPEP 609; Draw his form with next

FORM PTO-14499	atty. Dock-t no. 30727.001 IP1	Serval no. 09/518,501	
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT S	APPLICANT: METABASIS THERA	DEI ITICS	do
MALORING I TOM DISCHOSOME STRUCKING S	FILING DATE:	GROUP:	
(Use several sheets if necessin)	March 5, 1999	16378	las El
THE THE PARTY OF T		16Ursa	W 0 2
OTHER DOCUMENTS (Including Author, Ti	de, Date, Pertinent	Pages, ekch	1002

		160 g
,	OTK	Farquhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-0xo-1,3,2-
M	BA	Farquhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-0xo-1,3,2-0/296) oxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine and 9-[5'-(2-0xo-1,3,2-0ioxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[ß-D-Arabinofuranosyl]adenine 5'-Monophosphate," <u>J. Med. Chem.</u> 28: 1358-1361 (1985)
	88	Farguhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5- Fluoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem. 26: 1153-1158 (1983)
	BC	Freed, et al., "Evidence For Acyloxymethyl Esters of Pyrimidine 5'- Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," Biochem. Pharmac. 38: 3193-3198 (1989)
	8D	Hillers, et al., "Analogs of pyrimidinemono-and polynucleotides. IV. Phosphates of 1-(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." Khim Geterotski Soedin 5:678-683 (1978). Chem Abst. v 89 no 17; abst no 146864 g/u,
	BE	Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem. 27: 440-444 (1984)
	BF	Kryuchkov, et al., Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987)
	₿ G	Lok, et al., "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," <u>J. Antimicrob. Chemotherap.</u> 14: 93-99 (1984)
	вн	Ludeman, et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenyl ketophos phamide" and Similar Compounds Related to the Cyclophosphamide Metabolyte Aldophosphamide," J. Med Chem. 29, 716-727 (1986)
	81	Meier, et al., "Cyclic Saligenyl Phosphotreisters of 2', 3'-Dideoxy-2', 3'-didehydrothymidine (d4T) – A New Pro-Nucleotide Approach," <u>Bioorg. Med. Chem.</u> <u>Lett.</u> 7: 99-104 (1997)
	BJ	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prodrugs of Thiolnosinic Acid," J. Med. Chem. 22: 811-815 (1979)
	BK	Neldlein, et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Deisters and Cyclic Monoester Amides," Heterocycles 35: 1185-1203 (1993)

	laJ	
Examiner .	MMS Mr.	DATE CONSIDERED:
EXAMINER: line through cit communication	ation if not in conformance and	d, whether or not citation is in conformance with MPEP 609; Draw I not considered. Include a copy of this form with next

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMEND ATTY. DOCKET NO. 30727.001 IP1 09/518,501 APPLICANT: METABASIS THERAPEUTIO ANC.

(Use several sheets if necessary)

FEB 2 5 2007 5

FILING DATE: GROUP: March 5, 1999 1614

	OTH	IER DOCUMENTS (Including Kathor, Title, Date, Pertinent Pages (1) 2002
gu	BL	Nifant'ev, et al., "1,3,2, - Diazaphodsphorinanes", Zh. Obshch. Khim., Vol. 49, Re/2900
	ВМ	Nifantyev, et al.,"Synthesis and Structure of Some Stable Phospholane- Phospholanes," Phos. Sulfur & Silicon 113, 1-13 (1996)
	BN	Predvoditelev D., et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Organic</u> Chemistry of the USSR (English Translation 13:1489-1492 (1977))
	BO	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" <u>Journal of Organic Chemistry of the USSR (English Translation</u> 17:1156-1165 (1981)
	BP ·	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (Suppl) S-294 (1993)
	BQ	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," <u>Bull. Inst. Chem. Acad. Sin</u> , 41: 9-16 (1994)
	BR	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," <u>J. Med. Chem.</u> 37: 1857-1864 (1994)
	BS	Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999)
V	вт	Zon, et al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982)

			() r			
EXAMINER: Examiner	MMG	OM		DATE CONSIDERE	D: 7/9/	0
EXAMINER!	Initial if referentiation if not in	ence is consid	iered, wheth	er or not citation is in casidered. Include a cop	conformance way of this form	vith MPEP 609; Draw with next

Sheet

💠 💠 nood cirtl ablani (+) ngle exitq 🗅 eq

PTO/S8/08A (08-80)
Approved for use through 10/31/2002. COMB 1381-6031

U.S. Petent and Yrodoment Office: U.S. DEPARTMENT OF COMMERCE inder the Popercian Reduction Act of 1993, no parcent are required to respond to a calculate of information excess it contains a void Okta control number

Substitute for form 1448APTO

INFORMATION DISCLOSURE Statement by applicant

> (uso as many sheets as necessary) Of

Complato If Known 09/518,501 Application Number March 3, 2000 Filing Dow First Named Inventor Erion et al. 1624 Group Art Unit McKenzie, T. Examiner Name 45128.00013.RCE (CIP1) Attorney Decitet Number

Extrainer	CRO	U.S. Patent Documen		Octo of Publication of	Pogos, Ceberro, Uros, Witano Retorent
ntilizio*	No.'	Rumber Wind	of Cited Deturned	Cited Cosument MM-CD-YYYY	Posseguo er Actoria Rejunto Appeter
900		6,054,587	Reddy et al.	04/25/00	<u>'</u>
		6,110,903	Kasibhatla et al.	08/29/00	•
		6,284,748	Dang et al.	09/04/01	
		6,294,672	Reddy et al.	09/25/01	
		6,312,662	Erion et al.	11/06/01	
		6,399,782	Kasibhatla et al.	06/04/02	
TYZ		6,489,476	Dang et al.	12/03/02	7. Water 1. 17.

				FOREIGH PA	TENT DOCUMEN	T'S		
P	~:-		Foreign Patent Doc	ument	Natur of Patentes or	Ome of Publication of	Proper, Common Limit,	
Enterrings Initials	Cite No.	Office)	Number*	pison) FF Copy M	Applicant of Cited Document	Cited Consentat MM-DD-YYYY	'View Detrois Posicy හා වන්නය (Pyram Apper	75
-								
							<u>.</u>	زا

		non patent literature documents			
Exciminar Cito taxuela noma el Uno Cuchar (in CAPITAL LETTERS), Vito el 800 octubo (cono representato), Vito el 100 filam (besalt, mogostro, ja intellorio del contel, cymposium, estatog, cito), detto, popolo), valumo-bassa numbol(s), publishar, edy coder country entara publichad.					
		·			

Examiner Date Considered 9/16/09	 			
	Jon	Mille	4/16/	104

"EXAMINER: Intital II reference considered, whother or not election to in conformance with MPEP 800. From the through citation to not in conformance and necessities ed. Include copy of this form with next communication to applicant.

Burton Hour Statement. This form is continued to take 2.0 hours to complete. Time will vary degranding upon the needs of the individual case. Any comments on the amount of time you are required to complete this form chould be cent to the Chief Information Officer, U.S. Patent and Tradement Office, Washington, DC 20211. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Acceptant Commissional for Potentia, Washington, DC 20231.

BDILIDIVMANIFATYMA 61

^{*}Unique citation designation number. *See offsched Kines of U.S. Petent Decuments. *Enter Offse that based fire decument, by the two-lotter code (WIPO Standard ST.3). *For Japanese potent decuments, the indication of the year of the chapter must precede the code number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 & passion. *Applicant to to place a check mark have it English language Translation to stranslad.

Please type a plus aign (+) inside this box -> +

ATENT.

Sheet

PTO/SB/08A (08-00)

e type a plus sign (+) inside this box > + Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1895, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Kn wn **Application Number** 09/518,501 INFORMATION DISCLOSURE Filing Date March 3, 2000 STATEMENT BY APPLICANT First Named Inventor Erion et al. Group Art Unit 1624 (use as many sheets as necessary) T. McKenzie Examiner Name 45188.00013.RCE **Attorney Docket Number** of

		_		U.S. PATENT DOCU	MENTS	
Examiner	Cite	U.S. Patent Docu	ment	Name of Patentos or Applicant	Date of Publication of	Pages, Columns, Unes,
Initiats*	No.'	Number . IO	id Code ⁸ (DOMD)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
	ļ					
				······································		
			-			
				•		
						
			 			
						

				FOREIGN P	ATENT DOCUMEN	TS		
Examiner	Cite		Foreign Patent Doc		Name of Patentee or	Date of Publication of	Pages, Coterens, Lines,	7
laitints	No.1	Office	Number*	Kind Code* (/f Anores)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Referent Pussipus or Referent Figures Appear	7
								T
							~	十
		السر ا						†

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initiats	Cite No.1	Include name of the author (in CAPITAL LETYERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(a), volume-issue number(s), publisher, city and/or country where published.	T ²
1		FARQUHAR et al., "Synthesis and Antitumor Evaluation of Bis[pivaloyloxy)methyl] 2'-Deoxy-5- fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).	
n		LEFEBVRE, et al., Mononucleotide Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3'-Azido-2',3'-dideoxythymidine 5'-Monophosphate," J. Med. Chem., 38:3941-3950 (1995).	

Examiner **Date** Signatare Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw the through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁸ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁹ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissionar for Patents, Washington, DC 20231.

Plassa type o plus olga (+) Inside this box -> +

2004

Sheet

PEB 27

ATEND & TH

Substitute for form 1448A/PTO

nformation disclosure

statement by applicant

(use as many sheets as necessary)

Of

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0831-0031

U.S. Potent and Tredemath Criter: U.S. DEPARTMENT OF COMMERCE

Under the Paparount Roduction Act of 1995, no percens are required to respond to a collection of information unline it contains a veiled CMB control number

Complete If Known Application Number 09/518,501 Filing Date March 3, 2000 First Named Inventor Erion ot al. Group Art Unit 1624 Examiner Name T. McKenzie Attorney Doctat Number 032465.00013.RCE (CIP1)

				u.s. patent docu	MENTS	
Examinor Initiato* .	Cite No.'	U.S. Patent Docume Rumber Brus G	Com	Name of Petontes or Applicant of Clied Decument	Octo of Publication of Cited Document MM-DD-YYYY	Pogos, Coberno, Uros, Whoto Robrons Postagos er Robross Figuros Appeny
			\Rightarrow			

		· · · · · · · · · · · · · · · · · · ·			ATENT DOCUMEN	TS		=
Exeminer Initials	Cite No.'	Otteo,	Foreign Patent Dos Number*	timent Kind Code (f	Name of Patenten er Applicant of Cited Decement	Outs of Publication of Cited December MM-DD-YYYY	Propint, Colorina, Linna, Where Delevered Present or Relevered	\
							Pycon Agend .	Ë
							<u> </u>	╁

		(MON PATENT LITERATURE DOCUMENTS .	
	Y 3	CHON PAIENT EITERATURE DOCUMENTS	
Excuminar Initiato	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (other appropriate), title of the litem (book, magazine, journal, scale), symposium, catalog, etc.), date, page(o), volume-lesse number(s), publisher, city and/or country where published.	T*
81		Beaucage and Iyer, "The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications," <u>Tetrahedron</u> , 49(28):6123-6194 (1993).	
		Borch and Millard, "The Mechanism of Activation of 4-Hydroxycyclophosphamide," J. Med. Chem., 30:427-431 (1987).	
		Cooper et al., "Use of Carbohydrate Derivatives for Studies of Phosphorus Stereo-chemistry. Part II. Synthesis and Configurational Assignments of 1,-3,2-Oxathiaphosphorinan-2-ones and 1,3,2-Dioxaphosphorinan-2-thiones," J. Chem. Soc., Perk. Trans. 1, (10):1049-1052 (1974).	
		De Clercq et al., "A Novel Selective Broad-spectrum Anti-DNA Virus Agent," Nature, 323:464-467 (1986).	
		Farquhar et al., "Synthesis and Antitumor Evaluation of Bis[(pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).	

Examinar Signature	Date Considered	116/61

*EXAMINER: Initial it reference considered, whether or not cluster is in conformance with MPEP 800. Drawytho through chatton is not in conformance and not considered. Include copy of this form with next commutation to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Tradements Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}Unique citation designation number. *See attached Kindo of U.S. Patent Documents. *Enter Office that issued the document, by the two-latter code (AVIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emporer must precede the codel number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark have it English tanguage Translation is attached.



Pleaso type o plus cign (+) Inside this box -> + Under the Paparaent Reduction Act of 1899, no parcorn are require	U.S. Palent and Trydemen	PTO/SE/08A (08-00) Ed for upo liveugh 10/31/2002. QIAB 0851-0931 To Galco: U.S. DEPARTMENT OF COMMERCE Then unlose il contento e velid QMB central municer
Substitute for form 1448A/PTO	Co	omplete If Known
O PERCENT BY APPLICANT	Application Number	09/518,501
THE STATEMENT BY APPLICANT	Filing Data	March 3, 2000
78 2.7 PM FSTATEMENT BY APPLICANT	First Named Inventor	Erlon et al.
	Group Art Unit	1624
(use as many sheets as necessary)	Examiner Name	Y. McKenzie
Ten e eet 2 of 3	Attorney Docket Number	032465.00013.RCE (CIP1)

Exemptor Cito Institute Institute			non patent literature documents	
ritis and Bundgaard, "Prodrugs of Phosphates and Phosphonates: Novel Lipophilic o- acyloxyalkyl Ester Derivatives of Phosphate- or Phosphonate Containing Drugs Masking the Negative Charges of these Groups," Euro, J. Pharm. Sci., 4:49-59 (1996). Harada et al., "Resoluation of 1,3-alkanediols Via Chiral Spiroketals Derived from t- Menthone," Tetrahedron, 28(41):4843-4846 (1987). Khorana et al., "Cyclic Phosphates. III. Some General Observations on the Formation and Properties of Five-, Six- and Seven-membered Cyclic Phophate Esters," IACS, 79:430-436 (1957). Korba et al., "Liver-targeted Antiviral Nucleosides: Enhanced Antiviral Activity of Phosphatidyl-dideoxyguanosine Versus Dideoxyguanosine in Woodchuck Hepatitis Virus Infection In Vivo," Hepatology, 23(5):958-963 (1996). Lefebvre et al., "Mononucleoside Phosphotriester Derivatives with S-acyl-2-thioethyl Bioreversible Phosphate-protecting Groups: Intracellular Delivery of 3'azido- 2',3'dideoxythymidine 5'-monophosphate," I. Med. Chem., 38:3941-3950 (1995). Ludeman et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenylketophosphamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," J. Med. Chem., 29:716-727 (1986). McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT," J. Med. Chem., 36:1048-1052 (1993). Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," J. Org. Chem., 42(9):1549-1555 (1977). Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," J. Am. Chem. Soc., 112:6936-3942 (1990). Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Metabolity		· Cito	Include name of the outber (in CAPITAL LETTERS), title of the orticle (caes appropriate), title of the item (costs, magazine, journal, certal, symposium, catalog, etc.), date, pagasine, postume-issue numbers, publisher, city angles country when authlished	T ²
Menthone," Tetrahedron, 28(41):4843-4846 (1987). Khorana et al., "Cyclic Phosphates. III. Some General Observations on the Formation and Properties of Five-, Six- and Seven-membered Cyclic Phophate Esters," JACS, 79:430-436 (1957). Korba et al., "Liver-targeted Antiviral Nucleosides: Enhanced Antiviral Activity of Phosphatidyl-dideoxyguanosine Versus Dideoxyguanosine in Woodchuck Hepatitis Virus Infection In Vivo," Hepatology, 23(5):958-963 (1996). Lefebvre et al., "Mononucleoside Phosphotriester Derivatives with S-acyl-2-thioethyl Bioreversible Phosphate-protecting Groups: Intracellular Delivery of 3'azido-2',3'dideoxythymidine 5'-monophosphate," J. Med. Chem., 38:3941-3950 (1995). Ludeman et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenylketophosphamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," J. Med. Chem., 29:716-727 (1986). McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT," J. Med. Chem., 36:1048-1052 (1993). Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," J. Org. Chem., 42(9):1549-1555 (1977). Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," J. Am. Chem. Soc., 112:6936-3942 (1990). Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Keteelleri	4	1	acyloxyalkyl Ester Derivatives of Phosphate- or Phosphonate Containing Drugs Masking the Negative Charges of these Groups," <u>Euro. J. Pharm. Sci.</u> , 4:49-59 (1996).	
(1957). Korba et al., "Liver-targeted Antiviral Nucleosides: Enhanced Antiviral Activity of Phosphatidyl-dideoxyguanosine Versus Dideoxyguanosine in Woodchuck Hepatitis Virus Infection In Vivo," Hepatology, 23(5):958-963 (1996). Lefebvre et al., "Mononucleoside Phosphotriester Derivatives with S-acyl-2-thioethyl Bioreversible Phosphate-protecting Groups: Intracellular Delivery of 3'azido-2',3'dideoxythymidine 5'-monophosphate," J. Med. Chem., 38:3941-3950 (1995). Ludeman et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenylketophosphamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," J. Med. Chem., 29:716-727 (1986). McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT," J. Med. Chem., 36:1048-1052 (1993). Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," J. Org. Chem., 42(9):1549-1555 (1977). Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," J. Am. Chem. Soc., 112:6936-3942 (1990). Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Ketoally."			Harada et al., "Resoluation of 1,3-alkanediols Via Chiral Spiroketals Derived from 1-Menthone," <u>Tetrahedron</u> , 28(41):4843-4846 (1987).	-
Infection In Vivo," Hepatology, 23(5):958-963 (1996). Lefebvre et al., "Mononucleoside Phosphotriester Derivatives with S-acyl-2-thioethyl Bioreversible Phosphate-protecting Groups: Intracellular Delivery of 3'azido-2',3'dideoxythymidine 5'-monophosphate," J. Med. Chem., 38:3941-3950 (1995). Ludeman et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenylketophosphamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," J. Med. Chem., 29:716-727 (1986). McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT," J. Med. Chem., 36:1048-1052 (1993). Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," J. Org. Chem., 42(9):1549-1555 (1977). Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," J. Am. Chem. Soc., 112:6936-3942 (1990). Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Kernelley."			(1957).	
2',3'dideoxythymidine 5'-monophosphate," J. Med. Chem., 38:3941-3950 (1995). Ludeman et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenylketophosphamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," J. Med. Chem., 29:716-727 (1986). McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT," J. Med. Chem., 36:1048-1052 (1993). Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," J. Org. Chem., 42(9):1549-1555 (1977). Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," J. Am. Chem. Soc., 112:6936-3942 (1990). Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Kercelled.			Prosphatidyl-dideoxyguanosine Versus Dideoxyguanosine in Woodchuck Henritis Vinte	
Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," J. Med. Chem., 29:716-727 (1986). McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT," J. Med. Chem., 36:1048-1052 (1993). Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," J. Org. Chem., 42(9):1549-1555 (1977). Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," J. Am. Chem. Soc., 112:6936-3942 (1990). Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Kennelled	·	0	bioreversible Phosphate-protecting Groups: Intracellular Delivery of 3 arido	
Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," J. Org. Chem., 42(9):1549-1555 (1977). Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," L. Am. Chem. Soc., 112:6936-3942 (1990). Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Kespallarian			Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," <u>J. Med.</u> <u>Chem.</u> , 29:716-727 (1986).	
Priosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," J. Org. Chem., 42(9):1549-1555 (1977). Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," J. Am. Chem. Soc., 112:6936-3942 (1990). Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Ketoplan.			Derivatives of A21, "J. Med. Chem., 36:1048-1052 (1993).	
Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Ketsallad			Chem., 42(9):1549-1555 (1977).	
V Excess via the intramolecular Asymmetric Reduction of the Corresponding Ketopilot			Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," L. Am. Chem. Soc., 112:6936-3942 (1990).	
	Y		Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Ketoalkyl Diisopinocampheylborinate Intermediates," <u>Tetrahedron</u> , 38(3):761-764 (1997).	

Examiser-Signature Date Considered

*EXAMINER: Initial II reteronce considered, whether or no offician is in conformance with MPEP 809. Of the through distant is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 trours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patent and Trademark Office, Washington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Potents, · Washington, DC 20231.

¹ Unique dilation designation number. ² See attached Kinds of U.S. Potent Documents. ² Enter Office that issued the document, by the tere-letter code (WIPO Standard ST. 3). ° For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. If Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 II possible. ° Applicant is to place a check ment here if English Enguage Translation is attached.

XTENT.

neet

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1448A/PTO	Co	Complete if Known			
NFORMATION DISCLOSURE	Application Number	09/518,501			
	Filing Date	March 3, 2000			
STATEMENT BY APPLICANT	First Named Inventor	Erion et al.			
	Group Art Unit	1624			
(use as many sheets as necessary)	Examiner Name	T. McKenzie			
3 of 3	Attorney Docket Number	032465.00013.RCE (CIP1)			

·		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cita No.1	Include name of the suther (in CAPITAL LETTERS), title of the stricle (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ^a
81	1	Starrett, Jr. et al., "Synthesis, Oral Bloavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)," J. Med. Chem., 37:1857-1864 (1994).	
		Thomson et al., "Synthesis, Bioactivation and Anti-HIV Activity of the Bis(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Esters of the 5'-monophosphate of AZT," J. Chem. Soc., Perk. Trans. 1, (11):1239-1245 (1993).	
		Weber and Waxman, "Activation of the Anti-cancer Drug Ifosphamide by Rat Liver Microsomal P450 Enzymes," <u>Biochem. Pharm.</u> , 45(8):1685-1694 (1993).	
		Zon et al., "NMR Spectroscopic Studies of Intermediary Metabolites of Cyclophosphamide. A Comprehensive Kinetic Analysis of the Interconversion of cis- and trans-4- Hydroxycyclophosphamide with Aldophosphamide and Concomitant Partitioning of Aldophosphamide Between Irreversible Fragmentation and Reversible Conjugation Pathways," J. Med. Chem. 27:466-485 (1984).	

Examiner Date Signature Considered

*EXAMINER: Initial if reference considered, whether or not cultion is in conformance with MPEP 609. Draw one through chatton is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbots as indicated on the document under WIPO Standard ST. 15 if possible. ⁸ Applicant is to place a check mark here if English tanguage Translation is attached.

r			01,6/				Page 1 of 3	
		OPM PTO 144	JUN 2 8 2005 &	ATTY. DOCKET NO. 2358.0010002/RWE	/CJW	APPLICATION NO. 09/518,501		
!		ORM P10-1449	MATEMENT TRADEMAN	FIRST NAMED INVENTOR Erion et al.				
INFOR	RMATION	DISCLOSURE	MATEMENT	FILING DATE	FILING DATE ART UNIT			
			TRADENTA	March 3, 2000		1624		
EXAMINER		DOCUMENT	U.S. PA	TENT DOCUMENTS	T			
INITIAL		NUMBER	DATE	NAME	CLASS	SUB-ÇLASS	FILING DATE	
ar	AA1	3,404,178	10/01/1968	Roy, C.H.			10/07/1965	
	AB1	4,621,077	11/04/1986	Rosini et al.			06/08/1984	
	AC1	4,659,825	04/21/1987	Holy et al.			01/06/1984	
	AD1	4,705,651	11/10/1987	Staibano			10/11/1985	
	AE1	4,724,232	02/09/1988	Rideout et al.			09/17/1985	
	AF1	4,724,233	02/09/1988	De Clercq et al.			04/21/1986	
	AG1	4,777,163	10/11/1988	Bosies et al.			07/24/1987	
	AH1	4,808,716	02/28/1989	Holy et al.			04/25/1986	
	Al1	4,861,759	08/29/1989	Mitsuya et al.			08/11/1987	
/	AJ1	4,879,277	11/07/1989	Mitsuya et al.			08/11/1987	
	AK1	4,882,142	11/21/1989	Simon et al.			12/19/1988	
			FOREIGN	PATENT DOCUMEN	TS	, , ,		
EXAMINER		DOCUMENT	DATE	COUNTRY	61.466	CLUD CLASS	TOANICI ATION	
INITIAL		NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION Yes	
	AL						No	
	AM						Yes No	
	AN						Yes No	
	AO						Yes No	
	AP						Yes No	
	<u> </u>	OTHER	(Including Auth	or, Title, Date, Pertir	nent Pages, e	tc.)		
.•	AR							
	AS							
	AT							
EXAMINER	Din	1/1CK	Cest.			TE SONSIDERED		
EXAMINER: Hi	tial if r elier e red. Includ	ende considered, wh	ether or hot citation is with next communicate	s in conformance with MPE ion to Applicant.	P 609. Draw line	through offation if no	t in conformance	
			17	and the second second				

OIRE		
(n)		Page 2 of 3
JUN 2 8 2005 6	ATTY. DOCKET NO. 2358.0010002/RWE/CJW	APPLICATION NO. 09/518,501
	FIRST NAMED INVENTOR Erion et al.	
INFORMATION DISCLOSURE SUMMENT	FILING DATE	ART UNIT
	March 3, 2000	1624

					U.S.	PATENT DOCUME	NTS					
EXAMIN INITIAL	ER		DOCUME NUMBER		DATE	NAME		CLASE		SUB-CL/	ss	FILING DATE:
9	1	AA2	4,898,724		02/06/1990	Simon et al.						05/14/1987
		AB2	4,939,130)	07/03/1990	Jaeggi et al.			-			02/27/1989
		AC2	5,034,394		07/23/1991	Daluge						12/22/1989
		AD2	5,047,533	3	09/10/1991	Reist et al.						01/22/1990
		AE2	5,089,500)	02/18/1992	Daluge						05/08/1991
		AF2	5,153,183	3	10/06/1992	Kawabe et al.						05/06/1991
		AG2	5,210,085	5	05/11/1993	Liotta et al.						02/22/1991
		AH2	5,240,946	3	08/31/1993	Kinney et al.						04/29/1992
	1	Al2	5,246,937	7	09/21/1993	Harnden et al.						01/22/1992
		AJ2	5,366,965	5	11/22/1994	Strein		1				01/29/1993
0		AK2	5,480,875	5	01/02/1996	Isomura et al.						371 Date: 12/21/1994
		<u> </u>	<u> </u>		FOREIG	N PATENT DOCU	MENTS			\ -		122111994
EXAMIN INITIAL	ER		DOCUM		DATE	COUNTRY		CLAS	S	SUB-CL	ASS	TRANSLATION
	- -	AL										Yes No
		AM										Yes No
		AN										Yes No
		AO										Yes No
		AP										Yes No
			0	THER (Including Au	thor, Title, Date, P	ertinent Pag	ges, e	etc.)			
		AR			·							und
		AS										
		AT		1	//						/	
EXAMIN	ER	De	, ///	CE	en			D/	ATE (CONSTRE	RED	6,
EXAMINE and not	R: Init	ial if refer ed. Inclu	ence considing the copy of the	ered. whe	ether of not citation	n is in conformance with leation to Applicant.	MPEP 609. D	raw lin	e thro	ough citatio	n il no	t in conformance

403868_3.DOC

OIPE			
·	ST.		Page 3 of 3
FORM PTO-1449	زرن خ	ATTY. DOCKET NO. 2358.0010002/RWE/CJW FIRST NAMED INVENTOR Erion et al.	APPLICATION NO. 09/518,501
INFORMATION DISCLOSURE STATEMENT		FILING DATE March 3, 2000	ART UNIT 1624

				U.S. F	ATENT DOCUMENTS			
EXAMIN	IER		DOCUMENT					
INITIAL			NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
		AA3	5,532,225	07/02/1996	Reist et al.			07/31/1992
		AB3	5,583,122	12/10/1996	Benedict et al.			12/06/1985
		AC3	5,663,159	09/02/1997	Starrett, Jr. et al.			10/11/1994
		AD3	5,681,590	10/28/1997	Bechard et al.			371 Date: 07/26/1995
		AE3	5,721,219	02/24/1998	Ingall et al.			08/09/1995
		AF3	5,814,639	09/29/1998	Liotta et al.			02/16/1993
		AG3	5,840,716	11/24/1998	Ubasawa et al.			01/17/1997
		AH3	5,869,467	02/09/1999	Holy et al.			03/28/1995
(A		Al3	5,914,331	06/22/1999	Liotta et al.	1		06/07/1995
		AJ						
		AK .						
		на .		FOREIG	N PATENT DOCUMENTS		•	
EXAMIN INITIAL	IER		DOCUMENT	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION"
	<	AL)			Yes No
		AM						Yes No
		AN						Yes No
								Yes
		AO						No Yes
		AP	OTHER	(Including Au	thor, Title, Date, Pertinent	Pages, etc.)	<u> </u>	No
		AR						
		AS						
		AT		10			, /	 :
EXAMIN	ER	100	in Mici	/_	, as an a	DATE	ZONSIDERED	:
EXAMINE and not co	R: In/ti	ial if refer ed. Inclu	ence considered, we de copy of this form	ether of not citation with next communic	n is in conformance with MPEP 60 cation to Applicant.	9. Draw line thre	ough citation if not	in conformance

403868_3.DOC

SKGF Rev. 12/03/03